Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Oct 5;24(19):14927.
doi: 10.3390/ijms241914927.

Dysautonomia in Amyotrophic Lateral Sclerosis

Alexandra L Oprisan  1   2 , Bogdan Ovidiu Popescu  1   2   3
Affiliations
Review

Dysautonomia in Amyotrophic Lateral Sclerosis

Alexandra L Oprisan et al. Int J Mol Sci. .

Abstract

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease, characterized in its typical presentation by a combination of lower and upper motor neuron symptoms, with a progressive course and fatal outcome. Due to increased recognition of the non-motor symptoms, it is currently considered a multisystem disorder with great heterogeneity, regarding genetical, clinical, and neuropathological features. Often underestimated, autonomic signs and symptoms have been described in patients with ALS, and various method analyses have been used to assess autonomic nervous system involvement. The aim of this paper is to offer a narrative literature review on autonomic disturbances in ALS, based on the scarce data available to date.

Keywords: amyotrophic lateral sclerosis; autonomic function; neurodegeneration; non-motor symptoms.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Hardiman O., Al-Chalabi A., Chio A., Corr E.M., Logroscino G., Robberecht W., Shaw P.J., Simmons Z., van den Berg L.H. Amyotrophic lateral sclerosis. Nat. Rev. Dis. Primers. 2017;3:17071. doi: 10.1038/nrdp.2017.71. Erratum in Nat. Rev. Dis. Primers 2017, 3, 17085. - DOI - PubMed
    1. Jankovska N., Matej R. Molecular Pathology of ALS: What We Currently Know and What Important Information Is Still Missing. Diagnostics. 2021;11:1365. doi: 10.3390/diagnostics11081365. - DOI - PMC - PubMed
    1. McCluskey L., Vandriel S., Elman L., Van Deerlin V.M., Powers J., Boller A., Wood E.M., Woo J., McMillan C.T., Rascovsky K., et al. ALS-Plus syndrome: Non-pyramidal features in a large ALS cohort. J. Neurol. Sci. 2014;345:118–124. doi: 10.1016/j.jns.2014.07.022. - DOI - PMC - PubMed
    1. Longinetti E., Fang F. Epidemiology of amyotrophic lateral sclerosis: An update of recent literature. Curr. Opin. Neurol. 2019;32:771–776. doi: 10.1097/WCO.0000000000000730. - DOI - PMC - PubMed
    1. Qureshi M., Schoenfeld D.A., Paliwal Y., Shui A., Cudkowicz M.E. The natural history of ALS is changing: Improved survival. Amyotroph. Lateral Scler. 2009;10:324–331. doi: 10.3109/17482960903009054. - DOI - PubMed

MeSH terms